PTX 9.85 Pernix Therapeutics Holdings Inc. $PTX Hit a 52 week high of 10.00 Closing the day 11/03/14 at 9.85 +0.10 +1.03% With a day low of 9.58 and a total volume of 522,931.
PTX Recent Posts: http://investorshangout.com/Golf-Trust-Of-America-PTX-57271/
PTX Pernix Therapeutics Holdings Inc. Recent Headline News
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.64 (+0.01), PTX: 9.85 (+0.10), AKRX: 43.82 (-0.73), RPRX: 6.50 (+0.16), NKTR: 13.81 (+0.02)
Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST.
PTX: 9.85 (+0.10)
5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 6.23 (-0.48), ARWR: 6.52 (unch), PTX: 9.85 (+0.10), ADHD: 3.51 (-0.11), ZQK: 1.85 (+0.10), SALT: 4.84 (-0.05)
3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 5.00 (-0.18), PTX: 9.85 (+0.10), IVAC: 7.48 (+0.08)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 9.85 (+0.10), TGS: 3.42 (+0.04), RPRX: 6.50 (+0.16), NQ: 7.17 (-0.14), CVGI: 6.70 (+0.15)
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition.
PTX: 9.85 (+0.10), GSK: 45.49 (unch), POZN: 9.12 (+0.05)
POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 9.85 (+0.10), GSK: 45.49 (unch), POZN: 9.12 (+0.05)
Pernix Therapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014.
PTX: 9.85 (+0.10)
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
ENDP: 68.50 (+1.58), THRXV: 28.00 (+7.07), PTX: 9.85 (+0.10), AKRX: 43.82 (-0.73), DEPO: 15.63 (+0.23), THRX: 15.36 (-0.66)
Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company" , a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue.
PTX: 9.85 (+0.10), GSK: 45.49 (unch)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
TTS: 8.67 (+0.06), ACRX: 6.64 (+0.01), ENPH: 14.84 (-0.18), GBIM: 7.30 (+1.67), AMTX: 7.73 (-0.09), PTS.TO: 16.62 (-0.23), PCOM: 14.88 (-0.11), AFOP: 13.59 (+0.68), PTX: 9.85 (+0.10), HZNP: 12.95 (+0.01), GALT: 5.56 (+0.14), POZN: 9.12 (+0.05), NATL: 28.76 (+0.32)
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
PTX: 9.85 (+0.10)
Gyrotron Technology Inc. Elects Jan H. Loeb to Its Board of Directors
Marketwire - Tue Jul 22, 2:11PM CDT
Gyrotron Technology Inc. (PINKSHEETS: GYTI), a developer of innovative industrial technologies, announced today that Mr. Jan H. Loeb has been elected to its Board of Directors.
PTX: 9.85 (+0.10), TATT: 7.22 (-0.02)
Commit To Purchase Pernix Therapeutics Holdings At $7.50, Earn 23.9% Annualized Using Options
StockOptionsChannel.com - Fri Jul 11, 11:21AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $8.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
PTX: 9.85 (+0.10)
Pernix Therapeutics hires Sanjay Patel as CFO
M2 - Tue Jun 24, 6:33AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT TX) disclosed on Monday that it has appointed Sanjay Patel as its chief financial officer.
PTX: 9.85 (+0.10)
Pernix Therapeutics Appoints Chief Financial Officer
Business Wire - Mon Jun 23, 10:38AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Sanjay Patel as Chief Financial Officer.
PTX: 9.85 (+0.10)
Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix
PR Newswire - Thu Jun 19, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.
ACRX: 6.64 (+0.01), SQNM: 3.30 (+0.03), MDT: 68.15 (-0.01), PTX: 9.85 (+0.10), DARA: 0.91 (+0.06)
Pharmaceuticals Stocks Technical Momentum -- Research on Jazz Pharma, Omeros, Pernix Therapeutics Holdings, and Salix Pharma
PR Newswire - Mon Jun 16, 6:10AM CDT
On Friday, June 13, 2014, the NASDAQ Composite ended at 4,310.65, up 0.30%, the Dow Jones Industrial Average finished the day 0.25% higher at 16,775.74, and the S&P 500 closed at 1,936.16, up 0.31%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.44, down 0.02%, while the index has advanced 2.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Omeros Corp. (NASDAQ: OMER), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX) and Salix Pharmaceuticals Ltd (NASDAQ: SLXP). Free technical research on JAZZ, OMER, PTX and SLXP can be downloaded upon signing up at:
PTX: 9.85 (+0.10), JAZZ: 170.33 (+1.49), SLXP: 143.19 (-0.66), OMER: 17.33 (+0.76)
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
PTX: 9.85 (+0.10)
PTX Recent Posts: http://investorshangout.com/Golf-Trust-Of-America-PTX-57271/
PTX Pernix Therapeutics Holdings Inc. Recent Headline News
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.64 (+0.01), PTX: 9.85 (+0.10), AKRX: 43.82 (-0.73), RPRX: 6.50 (+0.16), NKTR: 13.81 (+0.02)
Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST. PTX: 9.85 (+0.10)
5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 6.23 (-0.48), ARWR: 6.52 (unch), PTX: 9.85 (+0.10), ADHD: 3.51 (-0.11), ZQK: 1.85 (+0.10), SALT: 4.84 (-0.05)
3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 5.00 (-0.18), PTX: 9.85 (+0.10), IVAC: 7.48 (+0.08)
5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 9.85 (+0.10), TGS: 3.42 (+0.04), RPRX: 6.50 (+0.16), NQ: 7.17 (-0.14), CVGI: 6.70 (+0.15)
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition. PTX: 9.85 (+0.10), GSK: 45.49 (unch), POZN: 9.12 (+0.05)
POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 9.85 (+0.10), GSK: 45.49 (unch), POZN: 9.12 (+0.05)
Pernix Therapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014. PTX: 9.85 (+0.10)
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
ENDP: 68.50 (+1.58), THRXV: 28.00 (+7.07), PTX: 9.85 (+0.10), AKRX: 43.82 (-0.73), DEPO: 15.63 (+0.23), THRX: 15.36 (-0.66)
Closing for Pernix Transaction to Acquire Treximet(R) Tablets for Migraine from GSK Delayed
Business Wire - Mon Aug 04, 8:15AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product. The Company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The Company and its lenders are also performing additional due diligence related to this supply issue. PTX: 9.85 (+0.10), GSK: 45.49 (unch)
Nasdaq stocks posting largest percentage decreases
AP - Tue Jul 29, 12:30PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
TTS: 8.67 (+0.06), ACRX: 6.64 (+0.01), ENPH: 14.84 (-0.18), GBIM: 7.30 (+1.67), AMTX: 7.73 (-0.09), PTS.TO: 16.62 (-0.23), PCOM: 14.88 (-0.11), AFOP: 13.59 (+0.68), PTX: 9.85 (+0.10), HZNP: 12.95 (+0.01), GALT: 5.56 (+0.14), POZN: 9.12 (+0.05), NATL: 28.76 (+0.32)
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014
Business Wire - Fri Jul 25, 8:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its second quarter 2014 financial results before the U.S. stock market opens on Monday, August 11, 2014 and has scheduled a conference call at 10:00 a.m. EDT that day to discuss the financial results.
PTX: 9.85 (+0.10)
Gyrotron Technology Inc. Elects Jan H. Loeb to Its Board of Directors
Marketwire - Tue Jul 22, 2:11PM CDT
Gyrotron Technology Inc. (PINKSHEETS: GYTI), a developer of innovative industrial technologies, announced today that Mr. Jan H. Loeb has been elected to its Board of Directors.
PTX: 9.85 (+0.10), TATT: 7.22 (-0.02)
Commit To Purchase Pernix Therapeutics Holdings At $7.50, Earn 23.9% Annualized Using Options
StockOptionsChannel.com - Fri Jul 11, 11:21AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $8.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
PTX: 9.85 (+0.10)
Pernix Therapeutics hires Sanjay Patel as CFO
M2 - Tue Jun 24, 6:33AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) disclosed on Monday that it has appointed Sanjay Patel as its chief financial officer. PTX: 9.85 (+0.10)
Pernix Therapeutics Appoints Chief Financial Officer
Business Wire - Mon Jun 23, 10:38AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Sanjay Patel as Chief Financial Officer. PTX: 9.85 (+0.10)
Agreements, Orphan Drug Designations, and Management Changes - Analyst Notes on Medtronic, DARA BioSciences, Sequenom, AcelRx and Pernix
PR Newswire - Thu Jun 19, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Medtronic, Inc. (NYSE: MDT), DARA BioSciences, Inc (NASDAQ: DARA), Sequenom Inc. (NASDAQ: SQNM), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) and Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3874-100free.
ACRX: 6.64 (+0.01), SQNM: 3.30 (+0.03), MDT: 68.15 (-0.01), PTX: 9.85 (+0.10), DARA: 0.91 (+0.06)
Pharmaceuticals Stocks Technical Momentum -- Research on Jazz Pharma, Omeros, Pernix Therapeutics Holdings, and Salix Pharma
PR Newswire - Mon Jun 16, 6:10AM CDT
On Friday, June 13, 2014, the NASDAQ Composite ended at 4,310.65, up 0.30%, the Dow Jones Industrial Average finished the day 0.25% higher at 16,775.74, and the S&P 500 closed at 1,936.16, up 0.31%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.44, down 0.02%, while the index has advanced 2.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Omeros Corp. (NASDAQ: OMER), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX) and Salix Pharmaceuticals Ltd (NASDAQ: SLXP). Free technical research on JAZZ, OMER, PTX and SLXP can be downloaded upon signing up at:
PTX: 9.85 (+0.10), JAZZ: 170.33 (+1.49), SLXP: 143.19 (-0.66), OMER: 17.33 (+0.76)
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector. PTX: 9.85 (+0.10)
